Lymphoma Clinical Trials in Nashville

Showing 281-300 of 654 trials

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

NCT03436862

This is a Phase II single-arm open-label study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression.

Hodgkin Lymphoma

SCRI Development Innovations, LLC37 participantsStarted May 2018

Denver, Colorado, United States • Kansas City, Missouri, United States • Nashville, Tennessee, United States +3 more locations

COMPLETEDPhase 2< 1 mile

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

NCT02181738

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.

Hodgkin Disease

Bristol-Myers Squibb294 participantsStarted Aug 2014

Los Angeles, California, United States • Los Angeles, California, United States • Atlanta, Georgia, United States +35 more locations

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Lymphoma Trials in Other Cities

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

A Study of BTX-1188 in Subjects With Advanced Malignancies

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Other Conditions in Nashville